Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abiraterone decanoate
- Development stage
- Approved
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Abiraterone decanoate (ASP5541, PRL-02) is a long-acting prodrug of abiraterone, a potent inhibitor of the enzyme CYP17A1 (17α-hydroxylase/C17,20-lyase). Developed by Astellas Pharma, it is designed as a sustained-release formulation for the treatment of prostate cancer. By inhibiting CYP17A1, the drug blocks the biosynthesis of androgens in the testes, adrenal glands, and prostate tumor tissue, thereby depriving androgen-sensitive prostate cancer cells of the hormones required for growth. The decanoate ester formulation aims to provide a longer duration of action compared to standard abiraterone acetate, potentially allowing for less frequent dosing via intramuscular injection. It is currently in Phase 2 clinical development.
- Other names
- abiraterone decanoate
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)AR (Adrenergic receptors)3β-HSD (3β-Hydroxysteroid Dehydrogenase/Δ5-4 isomerase type 1)SRD5A (Steroid 5-alpha-reductase)HSD17B2 (17β-HSD2 / HSD17B2)
Beyond the preview
Go deeper on abiraterone decanoate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abiraterone decanoate.